Kidney cancer is the most common cancer in the world, with an estimated 63,990 new cases in 2017. Among the primary kidney cancers, renal parenchymal cancer is the most common (estimated at around 80–90%) and the most complex to treat. The chances of developing cancer are about 1 in 63 in a person's lifetime, with a higher risk in men than women. Renal cell carcinoma incidence has increased over the last decade as a result of unhealthy lifestyle choices such as smoking, obesity, and a decline in physical activity. As the population ages and the incidence of kidney cancer rise, drugs in the pipeline for approval will drive the growth of the kidney cancer drug market.
The report titled "Kidney Cancer/Renal Cell Carcinoma Drugs Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025" offers strategic insights into the overall kidney cancer drugs market, along with the market size and estimates for the duration of 2015–2025. The research study in question provides an in-depth examination of multiple market segments based on drug type and geography.
The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year. Further cross-sectional analysis in terms of drug and constituent region-level markets is also included in this section.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global kidney cancer drugs market. Tools such as key player market positioning and appealing investment propositions provide readers with insights into the competitive landscape of the global kidney cancer/renal cell cancer drugs market. This report concludes with a company profiles section that highlights major information about the key players engaged in the global kidney cancer/renal cell carcinoma drugs market. In-depth competitive environment analysis and historical (2015) market size data are also provided in the report.
Furthermore, this report concludes with a profile of key market players currently enjoying prominent positions in the vascular grafts market. The key players profiled in this report are Active Biotech, Amgen, Bayer AG, Cipla Limited, F. Hoffmann-La Roche AG, Genentech, Inc., GlaxoSmithKline Plc, Novartis AG, Onyx, Pfizer, Inc., and others.
Based on the type of drug, the global kidney cancer drugs market is segmented as follows:
Sutent (Sunitinib)
Nexavar (Sorafenib)
Afinitor (Everolimus)
Votrient (Pazopanib)
Inlyta (Axitinib)
Avastin (Bevacizumab)
Torisel (Temsirolimus)
Proleukin (Aldesleukin)
Renal cell carcinoma is the most common type of cancer observed in developed countries. Sometimes surgical treatments are insufficient, and other treatments are required. One of the most promising treatments for kidney cancer is one of the target therapies. Sutent, Nexavar, and Votrient are commonly used drugs for renal cell carcinoma treatment. Sutent occupies the largest share, thus dominating the kidney cancer drug market. It is the most commonly prescribed first-line treatment drug for renal cell carcinoma. Votrient is anticipated to be the fastest-growing market in the forecast period. With the patent expiration of branded drugs, the entry of generics would have a negative impact on the kidney cancer drug market. However, novel drugs in phases 2 and 3 of clinical trials would further propel the growth of the kidney cancer drug market.
For the purpose of this study, the global kidney cancer drugs market is geographically categorized into:
North America
U.S.
Canada
Europe
U.K.
Germany
France
Rest of Europe
Asia Pacific
China
Japan
Rest of Asia
Latin America
Brazil
rest of Latin America
Middle East and Africa
GCC
Rest of the Middle East and Africa
In 2016, North America occupied the major share of the kidney cancer drug market, followed by Europe. North America and Europe have the highest incidences of kidney cancer, and the lowest are found in Africa and Asia. It is observed that kidney cancer is more prevalent in developed regions (around 59%).
In the U.S., around 65,000 new cases are diagnosed each year, and 13,500 deaths occur due to renal cell carcinoma annually. It is the seventh most common cancer in men and the ninth most common in women. The rise in incidences of kidney cancer, well-established healthcare infrastructure, and favorable reimbursement policies are some of the key reasons for the growth of the kidney cancer/renal cell carcinoma drug market in North America. Asia Pacific is the fastest-growing kidney cancer/renal cell carcinoma drug market. Rising geriatric populations, improvements in overall healthcare infrastructure, increased patient awareness, the availability of generics, and improved diagnostic technology are the key reasons for the growth of the lucrative Asia-Pacific market.
Frequently Asked Question:
The market for Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market is expected to reach USD$ 6,441.9 Mn in 2025.
The Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market is expected to see significant CAGR growth over the coming years, at 8.1%.
The report is forecasted from 2017 -2025.
The base year of this report is 2016.
Active Biotech, Amgen, Bayer AG, Cipla Limited, F. Hoffmann-La Roche AG, Genentech, Inc., GlaxoSmithKline Plc, Novartis AG, Onyx, Pfizer, Inc. are some of the major players in the global market.
